Literature DB >> 25109431

Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells.

Song Xue1, Ying-Xia Chen1, Shu-Kui Qin1, Ai-Zhen Yang2, Lin Wang1, Hai-Jun Xu2, Hai-Yun Geng1.   

Abstract

Raltitrexed is a specific inhibitor of thymidylate synthase (TS), which has been considered as a potential chemotherapeutic agent for the treatment of advanced gastric cancer. In the present study, the apoptosis mechanisms of raltitrexed in SGC7901 human gastric cancer cells were investigated. The cytotoxic activity of raltitrexed on SGC7901 cells was determined by cell counting kit-8 (CCK-8) assay. The CCK‑8 assay indicated that raltitrexed inhibits SGC7901 cell growth in a dose- and time-dependent manner. The morphological changes were observed by fluorescent microscopy, and characteristic morphological changes, including nuclear shrinkage and apoptotic bodies, were observed following Hoechst 33258 staining. The effects on apoptosis, cell cycle, mitochondrial transmembrane potential and reactive oxygen species (ROS) were measured by flow cytometry. The analysis revealed that raltitrexed exerted a growth inhibitory effect by inducing time-dependent apoptosis and cell-cycle arrest at the G0/G1 phase. In addition, a compromised mitochondrial membrane potential and overproduction of ROS demonstrated the involvement of the mitochondrial signaling pathway. Raltitrexed‑induced caspase‑3‑dependent apoptosis was identified using a caspase-3 activity assay and pretreatment with the caspase-3 inhibitor, Ac‑DEVD‑CHO (sequence, Ac-Asp-Glu-Val-Asp-CHO). The activity of caspase-3 was analyzed with a spectrometer. The protein expression levels of Bax, Bcl-2, cytochrome c, cleaved caspase-3 and TS were examined by western blot and the mRNA expression level of TS was detected by quantitative polymerase chain reaction. The analysis revealed that the protein levels of Bax, cytochrome c and cleaved caspase‑3 were significantly increased by raltitrexed, while Bcl-2 expression levels were reduced. Furthermore, raltitrexed increased the expression of the TS protein and mRNA in a time‑dependent manner. These results indicate that raltitrexed induces the apoptosis of SGC7901 cells through the caspase‑3‑dependent mitochondrial signaling pathway and upregulates the expression of the TS protein and mRNA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25109431     DOI: 10.3892/mmr.2014.2438

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

2.  Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.

Authors:  Qianyi Gong; Changfeng Song; Xiaotong Wang; Renjie Wang; Guoxiang Cai; Xin Liang; Jianwen Liu
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-10

3.  Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways.

Authors:  Hongchao Zhen; Guangxin Li; Pengfei Zhao; Ying Zhang; Jing Wang; Junxian Yu; Bangwei Cao
Journal:  Onco Targets Ther       Date:  2020-12-01       Impact factor: 4.147

4.  Short interfering RNA directed against the GOLPH3 gene enhances the effect of chemotherapy against oral squamous cell carcinoma by regulating Caspase3, Bcl2 and cytochrome-c expression.

Authors:  Guo-Hui Cui; Wen-Xin Li; Zhi-Yong Lin; Wei-Qun Zhang; Zhao-Hui Hu; Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.

Authors:  Gaetano Marverti; Gaia Gozzi; Eleonora Maretti; Angela Lauriola; Leda Severi; Francesca Sacchetti; Lorena Losi; Salvatore Pacifico; Stefania Ferrari; Glauco Ponterini; Eliana Leo; Maria Paola Costi; Domenico D'Arca
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

6.  Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells.

Authors:  Wen-Xiu Ding; Shu Liu; Jian-Xin Ma; Juan Pu; Hai-Jing Wang; Shu Zhang; Xin-Chen Sun
Journal:  Cancer Cell Int       Date:  2019-02-18       Impact factor: 5.722

7.  Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.

Authors:  Yonghua Bi; Dechao Jiao; Jianzhuang Ren; Xinwei Han
Journal:  Can J Gastroenterol Hepatol       Date:  2022-08-23

8.  Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4.

Authors:  Cong Hu; Xinhua Chen; Xu Lin; Jun Dai; Jiang Yu
Journal:  BMC Pharmacol Toxicol       Date:  2022-08-28       Impact factor: 2.605

9.  Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.

Authors:  Hongwei Zhao; Yubao Zhang; Jianmin Sun; Chao Zhan; Liang Zhao
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.